Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV‐infected patients receiving highly active antiretroviral therapy

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Medical Virology

• Publication date

  2008-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/jmv.21114PMID 18098145
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IL-6 and Its Circadian Secretion in Humans

  2005influential reference
• An immune origin of type 2 diabetes?

  2005cited by this paper
• High Plasma Levels of Intact and Cleaved Soluble Urokinase Receptor Reflect Immune Activation and Are Independent Predictors of Mortality in HIV-1-Infected Patients

  2005cited by this paper
• Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells.

  2005influential reference
• Cardiovascular risk and body-fat abnormalities in HIV-infected adults.

  2005cited by this paper
• Cardiovascular risk and body-fat abnormalities in HIV-infected adults.

  2005cited by this paper
• The role of TNF-α in insulin resistance

  2004cited by this paper
• Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy

  2004cited by this paper
• Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study.

  2004cited by this paper
• The role of TNF-alpha in insulin resistance.

  2004cited by this paper
• Soluble Urokinase Receptor Levels in Plasma During 5 Years of Highly Active Antiretroviral Therapy in HIV-1–Infected Patients

  2004influential reference
• Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV‐infected patients

  2004cited by this paper
• Decline in the AIDS and death rates in the EuroSIDA study: an observational study.

  2003cited by this paper
• Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels.

  2003cited by this paper
• Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study

  2003cited by this paper
• Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function.

  2003influential reference
• High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes.

  2002cited by this paper
• uPAR: a versatile signalling orchestrator

  2002cited by this paper
• Inflammatory status and insulin resistance

  2002cited by this paper
• Soluble Urokinase Plasminogen Activator Receptor Measurements: Influence of Sample Handling

  2001cited by this paper
• Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.

  2000cited by this paper
• Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.

  2000influential reference
• Association of Severe Insulin Resistance With Both Loss of Limb Fat and Elevated Serum Tumor Necrosis Factor Receptor Levels in HIV Lipodystrophy

  2000cited by this paper
• Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance.

  1999influential reference
• Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications.

  1998cited by this paper
• Structure, Function and Expression on Blood and Bone Marrow Cells of the Urokinase‐Type Plasminogen Activator Receptor, uPAR

  1997cited by this paper
• Effects of insulin on glucose turnover rates in vivo: isotope dilution versus constant specific activity technique.

  1996cited by this paper
• Calculation of substrate oxidation rates in vivo from gaseous exchange.

  1983cited by this paper

• Serum tumor necrosis factor-α levels in migraine: a registry for migraine (REFORM) study

  2026cites this paper
• The role of suPAR and related proteins in kidney, heart diseases, and diabetes

  2026cites this paper
• Associations between social behaviour and proinflammatory immune activation are modulated by age in a free-ranging primate population.

  2025cites this paper
• suPAR as a biomarker of support in different clinical settings.

  2025cites this paper
• Soluble urokinase plasminogen activator receptor biomarker is not a predictor of mortality in high-risk hip fracture patients

  2025cites this paper
• Association of plasma soluble urokinase plasminogen activator receptor concentrations and migraine with aura: a REFORM study

  2025cites this paper
• Biomarkers of chronic inflammation and cognitive decline: A prospective observational study

  2024cites this paper
• Pulmonary Congestion and Anemia in Hemodialysis: The Potential Link to Inflammation

  2024cites this paper
• Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients

  2024cites this paper
• suPAR in cardiovascular disease.

  2024cites this paper
• Soluble urokinase plasminogen activator receptor in vaginally collected amniotic fluid predicting fetal inflammatory response syndrome: a prospective cohort study

  2024cites this paper
• High-throughput proteomic analysis reveals systemic dysregulation in virally suppressed people living with HIV

  2023cites this paper
• The Association of suPAR with Cardiovascular Risk Factors in Young and Healthy Adults

  2023cites this paper
• SuPAR in major depression: Association with 26 weeks antidepressant response and 10-year depression outcomes

  2023cites this paper
• The accuracy of soluble urokinase-type plasminogen activator receptor for the diagnosis of neonatal sepsis: a meta-analysis

  2023cites this paper
• suPAR as a risk Prediction Biomarker in Extracorporeal Membrane Oxygenation

  2023cites this paper
• Chronic inflammation markers and cytokine-specific autoantibodies in Danish blood donors with restless legs syndrome

  2022cites this paper
• Predictive value of suPAR in AKI: a systematic review and meta-analysis

  2022cites this paper
• Concentrations of urinary neopterin, but not suPAR, positively correlate with age in rhesus macaques

  2022cites this paper
• Blood Cell Responses Following Heavy Alcohol Consumption Coincide with Changes in Acute Phase Reactants of Inflammation, Indices of Hemolysis and Immune Responses to Ethanol Metabolites

  2022cites this paper
• The Perspective of Vitamin D on suPAR-Related AKI in COVID-19

  2022cites this paper
• Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View

  2022cites this paper
• Personalised Approach to Diagnosing and Managing Ischemic Stroke with a Plasma-Soluble Urokinase-Type Plasminogen Activator Receptor

  2022cites this paper
• Soluble urokinase plasminogen activator receptor: a novel biomarker of pediatric community-acquired and hospitalacquired pneumonia.

  2022cites this paper
• Higher Cerebrospinal Fluid Soluble Urokinase-type Plasminogen Activator Receptor, But Not Interferon γ-inducible Protein 10, Correlate With Higher Working Memory Deficits

  2022cites this paper
• Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients

  2022cites this paper
• Serum levels of the soluble urokinase plasminogen activator receptor (suPAR) correlates with disease activity in early rheumatoid arthritis and reflects joint damage over time.

  2021cites this paper
• Elevated levels of soluble urokinase plasminogen activator receptor as a low-grade inflammation marker in schizophrenia: A case-control study.

  2021cites this paper
• suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department

  2021cites this paper
• Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms

  2021cites this paper
• Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation

  2021influential citation
• The Predictive Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention

  2021cites this paper
• suPAR Cut-offs for Stratification of Low, Medium, and High-risk Acute Medical Patients in the Emergency Department

  2021cites this paper
• Comparison of serum calprotectin, a marker of neutrophil activation, and other mediators of inflammation in response to alcohol consumption.

  2021cites this paper
• Linking Stressful Life Events and Chronic Inflammation Using suPAR (Soluble Urokinase Plasminogen Activator Receptor).

  2021cites this paper
• Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor

  2021cites this paper
• Does Soluble Urokinase-Type Plasminogen Activator Receptor Level Predicts the Occurrence of Inflammatory Complications in Maxillofacial Surgery?

  2021cites this paper
• Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications

  2021cites this paper
• Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis

  2021cites this paper
• Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction.

  2020cites this paper
• Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.

  2020cites this paper
• Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.

  2020cites this paper
• Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker of mortality in healthy, general and patient populations: protocol for a systematic review and meta-analysis

  2020cites this paper
• Serum Calprotectin, a Marker of Neutrophil Activation, and Other Mediators of Inflammation in Response to Various Types of Extreme Physical Exertion in Healthy Volunteers

  2020cites this paper
• Dynamic Changes of Heart Failure Biomarkers in Response to Parabolic Flight

  2020cites this paper
• SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease

  2020cites this paper
• The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis

  2020cites this paper
• Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.

  2020cites this paper
• Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea

  2020cites this paper
• The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine

  2019cites this paper
• Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood.

  2019cites this paper
• Healthy lifestyles reduce suPAR and mortality in a Danish general population study

  2019cites this paper
• Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Addition to High-Sensitivity Troponin I in Early Diagnosis of Acute Myocardial Infarction

  2019influential citation
• Inflammatory Pathways to Anemia in the Frail Elderly.

  2019cites this paper
• Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals.

  2019cites this paper
• Association of Adverse Experiences and Exposure to Violence in Childhood and Adolescence With Inflammatory Burden in Young People

  2019cites this paper
• Effect of simvastatin and ezetimibe on suPAR levels and outcomes.

  2018cites this paper
• Can serum soluble urokinase plasminogen activator receptor be an effective marker in the diagnosis of appendicitis and differentiation of complicated cases?

  2018cites this paper
• Decreased circulating urokinase plasminogen activator receptor (uPAR) concentration in acute episodes of bipolar disorder; could it be a reflection of axonal injury?

  2018cites this paper
• SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis

  2018cites this paper
• Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study*

  2018cites this paper
• Soluble Urokinase Plasminogen Activator Receptor (suPAR) is predictive of Non-AIDS Events during Antiretroviral Therapy-mediated Viral Suppression.

  2018cites this paper
• The role of suPAR in kidney diseases

  2017cites this paper
• How inflammation underlies physical and organ function in acutely admitted older medical patients.

  2017cites this paper
• The Relevance of Coding Gene Polymorphysms of Cytokines and Cellular Receptors in Sepsis

  2017cites this paper
• Soluble urokinase‐type plasminogen activator receptor (suPAR) and interleukin‐6 levels in hyperemesis gravidarum

  2017cites this paper
• Staphylococcus aureus - Plasminogen activation in vitro and prognostic markers in bacteraemic disease

  2017cites this paper
• A high-protein diet during hospitalization is associated with an accelerated decrease in soluble urokinase plasminogen activator receptor levels in acutely ill elderly medical patients with SIRS.

  2017cites this paper
• Soluble urokinase plasminogen activator receptor (suPAR) is prospective biomarker to evaluate treatment progress in children with pulmonary tuberculosis during maintenance phase

  2017cites this paper
• SERUM SOLUBLE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (SUPAR) AND INTERLEUKIN-6 LEVELS IN ENDOMETRIOSIS

  2017cites this paper
• Effects of Acute Exercise on Circulating Soluble Form of the Urokinase Receptor in Patients With Major Depressive Disorder

  2017cites this paper
• Acute Changes in Inflammatory Biomarker Levels in Recreational Runners Participating in a Marathon or Half-Marathon

  2016cites this paper
• Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis.

  2016cites this paper
• Plasma suPAR is lowered by smoking cessation: a randomized controlled study

  2016cites this paper
• A characterisation of low-grade inflammation and metabolic complications in HIV-infected patients.

  2016cites this paper
• Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study

  2016cites this paper
• Syddansk Universitet Soluble urokinase plasminogen activator receptor ( suPAR ) is a novel , independent predictive marker of myocardial infarction in HIV-1-infected patients a nested case-control study

  2016cites this paper
• suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease.

  2016cites this paper
• SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis.

  2016cites this paper
• Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View

  2016influential citation
• Nephrotic syndrome.

  2015cites this paper
• Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late‐onset Sepsis

  2015cites this paper
• Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years

  2015cites this paper
• Soluble urokinase plasminogen activator receptor--a valuable biomarker in systemic lupus erythematosus?

  2015cites this paper
• Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV‐1‐infected patients: a nested case‐control study

  2015cites this paper
• Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes

  2015cites this paper
• Primary Focal Segmental Glomerulosclerosis: Why Are Pieces of This Puzzle Still Missing?

  2015cites this paper
• suPAR: The unspecific marker for disease presence, severity and prognosis.

  2015cites this paper
• Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls

  2015cites this paper
• Soluble Urokinase Receptor and Chronic Kidney Disease.

  2015cites this paper
• Soluble Urokinase Plasminogen Activator Receptor : exploring its potential as a marker of cardiovascular disease development in black South Africans of the PURE study

  2015cites this paper
• Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China

  2015cites this paper
• Soluble urokinase-type plasminogen activator receptor (suPAR) – a possible biomarker for bacteremia in sepsis / Forma solubilă a receptorului pentru activatorul de plasminogen de tip urokinază (suPAR) – un biomarker posibil pentru bacteriemie în sepsis

  2015cites this paper
• Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia.

  2015cites this paper
• Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.

  2014cites this paper
• Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants

  2014cites this paper
• Clinical Value of Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Levels in Term Neonates with Infection or Sepsis: A Prospective Study

  2014cites this paper
• Urine soluble urokinase‐type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection

  2014cites this paper
• Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse Events

  2014cites this paper
• Unchanged Plasma Levels of the Soluble Urokinase Plasminogen Activator Receptor in Elective Coronary Artery Bypass Graft Surgery Patients and Cardiopulmonary Bypass Use

  2014cites this paper